当前位置:    首页  >  师资队伍  >  研究生导师  >  正文

侯旭奔 副研究员

侯旭奔,博士,副研究员,硕士生导师,入选山东大学青年学者未来计划。主要从事药物化学和药物分子设计研究,通过发展多尺度的计算策略进行基于靶点结构的药物设计和高通量虚拟筛选,并对活性先导化合物进行结构优化和生物活性评价。近年来以第一作者/通讯作者发表SCI论文20余篇,相关成果发表在J. Med. Chem.,J. Chem. Inf. Model., J. Biol. Chem. Eur. J. Med. Chem.,等领域权威期刊上。目前,主持国家自然科学基金、山东省自然科学基金、横向课题、国际合作课题等多个科研项目。

联系方式:

Email: hxb@sdu.edu.cn

Tel: 0531-88380720

通讯地址:山东省济南市文化西路44号山东大学趵突泉校区

学习及工作经历

  • 2007.9- 2011.6国精产品满18岁,药学专业,学士

  • 2011.8-2012.8共青团中央-山东大学研究生支教团(西部计划)

  • 2012.9- 2017.6国精产品满18岁,药物化学专业,硕博连读(导师:方浩教授)

  • 2015.10-2017.4纽约大学化学系,访问学者(导师:Prof. Yingkai Zhang)

  • 2017.7- 2018.8纽约大学化学系,博士后(导师:Prof. Yingkai Zhang)

  • 2018.12-至今国精产品满18岁,副研究员

    研究方向

  • 调控蛋白翻译后修饰相关靶点的药物设计、合成与生物活性研究。

  • 靶向蛋白-蛋白相互作用的新型小分子调控剂的设计、合成与生物活性研究

  • 基于分子力学、量子力学、人工智能算法发展靶点特异性的药物设计策略。

    主持科研项目

  • 新型LYP变构抑制剂的发现、优化以及抗自身免疫性疾病活性研究,国家自然科学基金青年科学基金项目(82003590)

  • 新型蛋白酪氨酸磷酸酶选择性抑制剂的合理设计、合成与生物活性研究,山东省自然科学基金青年科学基金项目(ZR2020QH342)

  • 山东大学青年学者未来计划(2019-2024)

  • 山东大学中澳健康科学研究中心合作研究项目

  • 山东大学-卡罗林斯卡医学院国际合作项目

  • 企业横向

    发表论文情况

  1. Chen C, Li X, Zhao H, Liu M, Du J, Zhang J, Yang X,Hou X*, Fang H*. Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity.J. Med. Chem.2022, 65(4):3667-3683.

  2. Liang H, Zhu Y, Zhao Z, Du J, Yang X,Fang H*,Hou X*. Structure-Based Design of 2-Aminopurine Derivatives as CDK2 Inhibitors for Triple-Negative Breast Cancer.Front. Pharmacol.2022, 13: 864342.

  3. Liang X, Li X, Zhao Z, Nie Y, Yao Z, Ren W, Yang X,Hou X*, Fang H*. Design, synthesis and biological evaluation of hydantoin derivatives as Mcl-1 selective inhibitors.Bioorg. Chem.2022, 121:105643.

  4. Liu M, Gao S, Elhassan RM,Hou X*, Fang H*. Strategies to overcome drug resistance using SHP2 inhibitors.Acta Pharm. Sin. B. 2021,11(12):3908-3924.

  5. Elhassan RM,Hou X*, Fang H*. Recent advances in the development of allosteric protein tyrosine phosphatase inhibitors for drug discovery.Med. Res. Rev.2022, 42(3):1064-1110.

  6. Hou X, Du J*, Fang H*. PTPRO is a therapeutic target and correlated with immune infiltrates in pancreatic cancer.J. Cancer.2021, 12(24):7445-7453.

  7. Teng KW, Tsai ST, Hattori T, Fedele C, Koide A, Yang C,Hou X, Zhang Y, Neel BG, O'Bryan JP, Koide S. Selective and noncovalent targeting of RAS mutants for inhibition and degradation.Nat Commun.2021, 12(1):2656.

  8. Hou X, et al. Inhibition of striatal-enriched protein tyrosine phosphatase by targeting computationally revealed cryptic pockets,Eur. J. Med. Chem., 2020,190:112131.

  9. Liu L, Liu R, Yang X,Hou X*, Fang H*. Design, synthesis and biological evaluation of tyrosine derivatives as Mcl-1 inhibitors.Eur. J. Med. Chem.,2020, 191:112142.

  10. Liang X, Fu H, Xiao P, Fang H*,Hou X*. Design, synthesis and biological evaluation of imidazolidine-2,4-dione and 2-thioxothiazolidin-4-one derivatives as lymphoid-specific tyrosine phosphatase inhibitors.Bioorg. Chem.,2020, 103:104124.

  11. Du J, Liu L, Liu B, Yang J,Hou X*, Yu J*, Fang H*. Structure-based virtual screening, biological evaluation and biophysical study of novel Mcl-1 inhibitors.Future Med. Chem.,2020,12(14):1293-1304.

  12. Du J, Li W, Liu B, Zhang Y, Yu J,Hou X*,Fang H*. An in silico mechanistic insight into HDAC8 activation facilitates the discovery of new small-molecule activators.Bioorg. Med. Chem.,2020, 28(16):115607.

  13. Lu J,Hou X, Wang C, Zhang Y. Incorporating Explicit Water Molecules and Ligand Conformation Stability in Machine-Learning Scoring Functions.J. Chem. Inf. Model.2019, 59(11):4540-4549.

  14. Chen C, Nie Y, Xu G, Yang X, Fang H,Hou X*. Design, synthesis and preliminary bioactivity studies of indomethacin derivatives as Bcl-2/Mcl-1 dual inhibitors.Bioorg. Med. Chem.2019, 27(13):2771-2783.

  15. Chen C, Yang X, Fang H*,Hou X*. Design, synthesis and preliminary bioactivity evaluations of 8-hydroxyquinoline derivatives as matrix metalloproteinase (MMP) inhibitors.Eur. J. Med. Chem.2019, 181:111563.

  16. Li K#,Hou X#, Li R#, Bi W#, Yang F, Chen X, Xiao P, Liu T, Lu T, Zhou Y, Tian Z, Shen Y, Zhang Y, Wang J, Fang H, Sun J*, Yu X.* Identification and structure-function analyses of an allosteric inhibitor of the tyrosine phosphatase PTPN22.J. Biol. Chem.2019, 294(21):8653-8663.

  17. Hou X, Rooklin D, Yang D, Liang X, Li K, Lu J, Wang C, Xiao P, Zhang Y, Sun JP, Fang H. Computational Strategy for Bound State Structure Prediction in Structure-Based Virtual Screening: A Case Study of Protein Tyrosine Phosphatase Receptor Type O Inhibitors.J. Chem. Inf. Model.2018, 58(11):2331-2342.

  18. Hou X, et al. Resveratrol serves as a protein-substrate interaction stabilizer in human SIRT1 activation.Sci. Rep.,2016,6, 38186.

  19. Hou X, et al. Protein Flexibility in Docking-Based Virtual Screening: Discovery of Novel Lymphoid-Specific Tyrosine Phosphatase Inhibitors Using Multiple Crystal Structures.J. Chem. Inf. Model.2015, 55(9):1973-1983.

  20. Hou X, et al. Enhancing the Sensitivity of Pharmacophore-Based Virtual Screening by Incorporating Customized ZBG Features: A Case Study Using Histone Deacetylase 8.J. Chem. Inf. Model.2015, 55(4):861-871.

  21. Hou X, et al. Fast Identification of Novel Lymphoid Tyrosine Phosphatase Inhibitors Using Target-Ligand Interaction-Based Virtual Screening.J. Med. Chem.2014, 57, 9309-9322.

  22. Hou X, et al. How to improve docking accuracy of AUTODOCK4.2: A case study using different electrostatic potentials.J. Chem. Inf. Model.2013, 53(1):188-200.

    获奖情况

    《药学学报》药学前沿论坛青年论坛优秀论文三等奖

    山东大学青年教师讲课比赛二等奖、三等奖

    山东大学青年教师讲课比赛青年教学能手

    全国药物化学学术会议优秀墙报奖

    山东省研究生优秀科技创新成果奖

    山东省优秀共青团员

    “挑战杯”全国大学生课外学术科技作品竞赛二等奖

    中国专利年会“校园发明与创新”金奖

    学术兼职情况

    Eur. J. Med. Chem., Theranostics, Bioorg. Chem., Bioorg. Med. Chem., Phys. Chem. Chem. Phys.等杂志审稿人

    Member of The New York Academy of Sciences

    中国药学会会员,中国化学会会员

上一篇:刘武 教授

下一篇:金康 研究员